Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | Director · President and CEO | August 06, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date August 06, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 961 |
Reported balance
After 2026-08-06 transaction · row 1
1 source rowRow 1 · 2026-08-06 · Exercise / conversion · Acquired 961 · Balance 961 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-06 · Exercise / conversion · Disposed 961 · Balance 0 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2: On August 6, 2025, the reporting person was granted 17,300 (961 post-split) RSUs, vesting on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2: On August 6, 2025, the reporting person was granted 17,300 (961 post-split) RSUs, vesting on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 11, 2026 01:38 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 961 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-343079 · ownership.xml · derivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 961 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On August 6, 2025, the reporting person was granted 17,300 (961 post-split) RSUs, vesting on the first anniversary of the date of grant. F2 · derivative.expiration_date: On August 6, 2025, the reporting person was granted 17,300 (961 post-split) RSUs, vesting on the first anniversary of the date of grant. Read SEC document |
| August 06, 2026 Filed Aug 11, 2026 01:38 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 961 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-343079 · ownership.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:32 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 17,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-105930 · ownership.xml · derivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,300 Underlying: Common Stock · 17,300 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: The RSUs vest in full on the first anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs vest in full on the first anniversary of the date of grant. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 20:35 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 5 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-097267 · ownership.xml · derivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12 Underlying: Common Stock · 17 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On July 17, 2024, the reporting person was granted 12,825 (17 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025. F2 · derivative.expiration_date: On July 17, 2024, the reporting person was granted 12,825 (17 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 20:35 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock (post-reverse split May ACTIVE) | 5 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-097267 · ownership.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:35 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 2 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032197 · ownership.xml · derivative · entry 4 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: On June 7, 2022, the reporting person was granted 11,000 (7 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023. F3 · derivative.expiration_date: On June 7, 2022, the reporting person was granted 11,000 (7 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:35 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 2 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-032197 · ownership.xml · nonDerivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| March 02, 2025 Filed Mar 4, 2025 21:35 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 3 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032197 · ownership.xml · derivative · entry 3 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4 Underlying: Common Stock · 3 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 16,500 (11 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024. F2 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 16,500 (11 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024. Read SEC document |
| March 02, 2025 Filed Mar 4, 2025 21:35 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 3 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-032197 · ownership.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| August 08, 2024 Filed Aug 9, 2024 20:33 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 272 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-094816 · ownership.xml · derivative · entry 4 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 272 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: On August 9, 2022, the reporting person was granted 23,958 (544 post-split) RSUs, vesting in two approximately equal annual installments beginning on August 8, 2023. F3 · derivative.expiration_date: On August 9, 2022, the reporting person was granted 23,958 (544 post-split) RSUs, vesting in two approximately equal annual installments beginning on August 8, 2023. Read SEC document |
| August 08, 2024 Filed Aug 9, 2024 20:33 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 42 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-094816 · ownership.xml · derivative · entry 3 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41 Underlying: Common Stock · 42 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On August 9, 2022, the reporting person was granted 5,500 (125 post-split) RSUs, vesting in three approximately equal annual installments beginning on August 8, 2023. F2 · derivative.expiration_date: On August 9, 2022, the reporting person was granted 5,500 (125 post-split) RSUs, vesting in three approximately equal annual installments beginning on August 8, 2023. Read SEC document |
| August 08, 2024 Filed Aug 9, 2024 20:33 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 272 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-094816 · ownership.xml · nonDerivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| August 08, 2024 Filed Aug 9, 2024 20:33 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 42 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-094816 · ownership.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 20:35 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 12,825 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-084952 · ownership.xml · derivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,825 Underlying: Common Stock · 12,825 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: The RSUs vest in three approximately equal annual installments beginning on July 17, 2025. F2 · derivative.expiration_date: The RSUs vest in three approximately equal annual installments beginning on July 17, 2025. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:12 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 3,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025915 · ownership.xml · derivative · entry 4 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,667 Underlying: Common Stock · 3,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: On June 7, 2022, the reporting person was granted 11,000 RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023. F3 · derivative.expiration_date: On June 7, 2022, the reporting person was granted 11,000 RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:12 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 3,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-025915 · ownership.xml · nonDerivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 21:12 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025915 · ownership.xml · derivative · entry 3 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 16,500 RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024. F2 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 16,500 RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 21:12 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-025915 · ownership.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| January 28, 2024 Filed Jan 30, 2024 23:04 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 1,833 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-009003 · ownership.xml · derivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On January 29, 2021, the reporting person was granted 5,500 RSUs, vesting in three approximately equal annual installments beginning on January 28, 2022. F2 · derivative.expiration_date: On January 29, 2021, the reporting person was granted 5,500 RSUs, vesting in three approximately equal annual installments beginning on January 28, 2022. Read SEC document |
| January 28, 2024 Filed Jan 30, 2024 23:04 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 1,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-009003 · ownership.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 12:41 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 1,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045263 · doc4.xml · derivative · entry 4 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,667 Underlying: Common Stock · 1,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: On August 9, 2022, the reporting person was granted 5,500 RSUs, vesting in three approximately equal installments beginning on August 8, 2023. F3 · derivative.expiration_date: On August 9, 2022, the reporting person was granted 5,500 RSUs, vesting in three approximately equal installments beginning on August 8, 2023. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 12:41 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 11,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045263 · doc4.xml · derivative · entry 3 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,979 Underlying: Common Stock · 11,979 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On August 9, 2022, the reporting person was granted 23,958 RSUs, vesting in two approximately equal installments beginning on August 8, 2023. F2 · derivative.expiration_date: On August 9, 2022, the reporting person was granted 23,958 RSUs, vesting in two approximately equal installments beginning on August 8, 2023. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 12:41 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 1,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045263 · doc4.xml · nonDerivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 12:41 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 11,979 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045263 · doc4.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:44 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001209191-23-016789 · doc4.xml · derivative · entry 4 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2033-03-02 F4 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on March 2, 2024. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:44 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016789 · doc4.xml · derivative · entry 3 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: The RSUs vest in three approximately equal annual installments beginning on March 2, 2024. F3 · derivative.expiration_date: The RSUs vest in three approximately equal annual installments beginning on March 2, 2024. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:44 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 3,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016789 · doc4.xml · derivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,334 Underlying: Common Stock · 3,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On June 7, 2022, the reporting person was granted 11,000 RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023. F2 · derivative.expiration_date: On June 7, 2022, the reporting person was granted 11,000 RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:44 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 3,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016789 · doc4.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| January 29, 2023 Filed Jan 30, 2023 18:04 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 1,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005420 · doc4.xml · derivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,833 Underlying: Common Stock · 1,834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On January 29, 2021, the reporting person was granted 5,500 RSUs, vesting in three approximately equal annual installments beginning on January 29, 2022. F2 · derivative.expiration_date: On January 29, 2021, the reporting person was granted 5,500 RSUs, vesting in three approximately equal annual installments beginning on January 29, 2022. Read SEC document |
| January 29, 2023 Filed Jan 30, 2023 18:04 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 1,834 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-005420 · doc4.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:08 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 23,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-045183 · doc4.xml · derivative · entry 3 Lamothe Jeffrey G. · CIK 0001679967 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,958 Underlying: Common Stock · 23,958 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F4 · derivative.exercise_date: The RSUs vest in two approximately equal annual installments beginning on August 8, 2023. F4 · derivative.expiration_date: The RSUs vest in two approximately equal annual installments beginning on August 8, 2023. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:08 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001209191-22-045183 · doc4.xml · derivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2032-08-08 F3 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on August 8, 2023. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:08 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-045183 · doc4.xml · derivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: The RSUs vest in three approximately equal annual installments beginning on August 8, 2023. F2 · derivative.expiration_date: The RSUs vest in three approximately equal annual installments beginning on August 8, 2023. Read SEC document |
| June 07, 2022 Filed Jun 7, 2022 21:25 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034879 · doc4.xml · derivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires not disclosed F1 · security: As previously disclosed in a Form 4 filed on March 4, 2022, the reporting person was granted 11,000 options on such date. At the time of the grant, there were insufficient shares available for issuance under the Aptevo Therapeutics Inc. 2018 Stock Incentive Plan to make the full grant of equity award to the reporting person that was approved for issuance by Aptevo Therapeutics Inc.'s Compensation Committee. As such, the equity award was split into two separate grants with the first portion of 11,000 options granted on March 4, 2022 and the second portion of 11,000 restricted stock units granted on June 7, 2022, following stockholder approval of an increase in shares available for issuance under the Aptevo Therapeutics Inc. 2018 Stock Incentive Plan (as Amended and Restated). F2 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: The RSU vests in three approximately equal annual installments beginning on March 3, 2023. F3 · derivative.expiration_date: The RSU vests in three approximately equal annual installments beginning on March 3, 2023. Read SEC document |
| March 04, 2022 Filed Mar 4, 2022 23:11 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001209191-22-016453 · doc4.xml · derivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2032-03-03 F1 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on March 3, 2023. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 23:00 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 1,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-22-000112 · lamothe.xml · derivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,667 Underlying: Common Stock · 1,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On January 29, 2021, the reporting person was granted 5,500 RSUs, vesting in three approximately equal annual installments beginning on January 29, 2022. F2 · derivative.expiration_date: On January 29, 2021, the reporting person was granted 5,500 RSUs, vesting in three approximately equal annual installments beginning on January 29, 2022. Read SEC document |
| January 29, 2022 Filed Feb 1, 2022 23:00 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 1,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-22-000112 · lamothe.xml · nonDerivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| January 29, 2021 Filed Feb 18, 2021 02:02 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-21-000145 · lamothe.xml · derivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSU vests in three approximately equal annual installments beginning on January 29, 2022. F3 · derivative.expiration_date: The RSU vests in three approximately equal annual installments beginning on January 29, 2022. Read SEC document |
| January 29, 2021 Filed Feb 18, 2021 02:02 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $33.50 | $0.00 |
DisclosureSEC source: 0001019056-21-000145 · lamothe.xml · derivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-01-29 F1 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on January 29, 2022. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:51 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 2,140 | Not disclosed Strike: $8.56 | Not disclosed |
DisclosureSEC source: 0001019056-20-000454 · lamothe.xml · derivative · entry 9 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,140 Underlying: Common Stock · 2,140 shares Expires 2030-07-26 F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F11 · derivative.exercise_date: These options will vest in three approximately equal annual installments beginning on the one year anniversary of the date of grant. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:51 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 7,380 | Not disclosed Strike: $8.56 | Not disclosed |
DisclosureSEC source: 0001019056-20-000454 · lamothe.xml · derivative · entry 8 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,380 Underlying: Common Stock · 7,380 shares Expires 2030-07-26 F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F10 · derivative.exercise_date: These options vest in full on the one year anniversary of the date of grant. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:51 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 4,814 | Not disclosed Strike: $21.28 | Not disclosed |
DisclosureSEC source: 0001019056-20-000454 · lamothe.xml · derivative · entry 7 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,814 shares Expires 2029-02-28 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F9 · derivative.exercise_date: This stock option award provides for vesting in three approximately equal annual installments beginning on February 28, 2020. Prior to July 27, 2020, all but 3,210 shares of the issuer's common stock underlying this stock option had vested. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:51 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 4,814 | Not disclosed Strike: $43.82 | Not disclosed |
DisclosureSEC source: 0001019056-20-000454 · lamothe.xml · derivative · entry 6 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,814 shares Expires 2028-03-09 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F8 · derivative.exercise_date: This stock option award provides for vesting in three approximately equal annual installments beginning on March 9, 2019. Prior to July 27, 2020, all but 1,605 shares of the issuer's common stock underlying this stock option had vested. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:51 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 2,407 | Not disclosed Strike: $30.10 | Not disclosed |
DisclosureSEC source: 0001019056-20-000454 · lamothe.xml · derivative · entry 5 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,407 shares Expires 2027-06-01 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F7 · derivative.exercise_date: This stock option award vested over three years, and the final one-third vested on June 1, 2020. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:51 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 2,407 | Not disclosed Strike: $27.44 | Not disclosed |
DisclosureSEC source: 0001019056-20-000454 · lamothe.xml · derivative · entry 4 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,407 shares Expires 2027-02-24 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F6 · derivative.exercise_date: This stock option award vested over three years, and the final one-third vested on February 24, 2020. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:51 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 3,128 | Not disclosed Strike: $41.58 | Not disclosed |
DisclosureSEC source: 0001019056-20-000454 · lamothe.xml · derivative · entry 3 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,128 shares Expires 2026-02-28 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F5 · derivative.exercise_date: This stock option award vested over three years, and the final one-third vested on March 1, 2019. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:51 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 1,928 | Not disclosed Strike: $35.70 | Not disclosed |
DisclosureSEC source: 0001019056-20-000454 · lamothe.xml · derivative · entry 2 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,928 shares Expires 2022-03-09 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F4 · derivative.exercise_date: This stock option award vested in full on March 10, 2018. This award was originally part of a grant from Emergent dated March 11, 2015, of which two-thirds were vested at the time of conversion to the issuer's equity pool. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 31, 2020 20:51 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 2,695 | Not disclosed Strike: $34.58 | Not disclosed |
DisclosureSEC source: 0001019056-20-000454 · lamothe.xml · derivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,695 shares Expires 2021-03-10 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F2 · derivative.exercise_date: This stock option award vested on March 10, 2017. This award was originally part of a grant from Emergent BioSolutions Inc. ("Emergent") dated March 11, 2014, of which two-thirds were vested at the time of conversion to the issuer's equity pool. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| February 18, 2020 Filed Mar 19, 2020 22:34 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 134,800 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001019056-20-000241 · lamothe.xml · derivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,800 Underlying: Common Stock · 134,800 shares Expires 2030-02-17 F1 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on February 17, 2021. Read SEC document |
| November 01, 2019 Filed Nov 6, 2019 01:53 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 135,384 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001019056-19-000614 · lamothe.xml · derivative · entry 1 Lamothe Jeffrey G. · CIK 0001679967 · SVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,384 Underlying: Common Stock · 135,384 shares Expires 2029-10-31 F1 · derivative.exercise_date: The options vest on November 1, 2020, the one-year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.